-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

623.O2.6 623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Clinical Trials for Marginal Zone Lymphoma, Waldenstrom's Macroglobulinemia and Hairy Cell Leukemia

Symposia: Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Combination therapy, Lymphoid Leukemias, Research, Clinical trials, Adult, Antibody Therapy, Lymphomas, Drug development, Non-Hodgkin lymphoma, CLL, B Cell lymphoma, Clinical Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Education, Diseases, Indolent lymphoma, Treatment Considerations, Biological therapies, Immunotherapy, Lymphoid Malignancies, Monoclonal Antibody Therapy, Study Population, Human, Measurable Residual Disease
Monday, December 9, 2024: 2:45 PM-4:15 PM
Marriott Grand Ballroom 11-13 (Marriott Marquis San Diego Marina)
Moderators:
Christine E. Ryan, MD, Dana-Farber Cancer Institute and Annarita Conconi, Nuovo Ospedale degli Infermi
Disclosures:
Ryan: AstraZeneca: Honoraria; Genentech: Other: Institutional research funding. Conconi: Incyte: Speakers Bureau; Novartis: Honoraria; Janssen: Speakers Bureau; Abbvie: Speakers Bureau; Astra Zeneca: Speakers Bureau; Gilead: Honoraria, Speakers Bureau; Roche: Honoraria, Speakers Bureau; Beigene: Speakers Bureau.

The Oral session 2 groups the top scored studies in FL and also MZL. One abstract in WM has been included. All this studies are clinical trials.
2:45 PM

Christian Buske, MD1, Efstathios Kastritis, MD, PhD2*, Alexander Grunenberg, MD3*, Andreas Viardot, MD, PhD3, Dajana Kaczynski1*, Heike Mund4*, Katja Gutmair5*, Matthias Zingerle6*, Paul Duewel7*, Susanne Saussele, MD8, Björn Schöttker9*, Ullrich Graeven, MD10*, Martin Dreyling, MD11, Andrea Kerkhoff, MD12*, Thomas Weber13*, Holger F. Hebart, MD14, Ralf Ulrich Trappe, MD15*, Lisa Kaiser1*, Elke Runge1*, Jasmin Mark1*, Simone Ferrero, MD16, Daniela Drandi17*, Falko Fend, MD18*, Irina Bonzheim19*, Eva Hoster, PhD, Prof.20*, Jens Dreyhaupt21* and Meletios A. Dimopoulos, MD2

1Institute of Experimental Cancer Research, University Hospital Ulm, Ulm, Germany
2Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
3Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
4University Hospital Ulm, Ulm, Germany
5Institute of Medical Information, University of Munich, Munich, Germany
6Haematology and Oncology, Munich-Pasing MVZ GmbH,, Munich, Germany
7Oncological Specialist Practice, Studiengesellschaft Onkologie Bielefeld, Bielefeld, Germany
8Universitätsmedizin Mannheim, Ilvesheim, Germany
9Joint practice for Haematology and Internal Oncology, Wuerzburg, Germany
10Department of Hematology, Oncology and Gastroenterology, Medical Clinic I, Hospital Maria Hilf GmbH, Mönchengladbach, Germany, Mönchengladbach, DEU
11Department of Internal Medicine 3, Ludwig-Maximilians-Universität (LMU), Munich, Germany
12Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany
13Department of Internal Medicine IV, Haematology and Oncology, University Hospital Halle (Saale), Martin-Luther-University Halle-Wittenberg, Halle, Germany
14Department of Internal Medicine, Hematology and Oncology, Stauferklinikum, Mutlangen, Mutlangen, Germany
15Department of Internal Medicine III, DIAKO Ev. Diakonie-Krankenhaus, Bremen, Germany
16Department of Molecular Biotechnology and Health Sciences, Hematology Division, University of Torino, Torino, TO, Italy
17Hematology Division I, Department of Molecular Biotechnologies and Health Sciences, University of Turin/University Hospital A.O.U. “Città della Salute e della Scienza”, Torino, Italy, Italy
18University of Tübingen, Department of Pathology and Neuropathology, Tuebingen, Germany
19Institute of Pathology, Tuebingen, DEU
20Institute of Medical Data Processing, Biometrics and Epidemiology (IBE), LMU Munich, Munich, Germany
21Institute of Epidemiology and Medical Biometry, University of Ulm, Ulm, Germany

3:00 PM

John F. Seymour, MBBS, PhD1, Constantine S. Tam, MD, MBBS2, Chan Y. Cheah, MBBS DMSc3,4,5, Ricardo D. Parrondo, MD6, John N. Allan, MD7, Judith Trotman, FRACP8, Ranjana H. Advani, MD9, Herbert A. Eradat, MD10, Pier Luigi Zinzani, MD, PhD11, Masa Lasica, MBBS, BMedSci, FRACP, FRCPA12*, Steven P. Treon, MD, PhD, FRCP13, Xiangmei Chen14*, Kunthel By, PhD15*, Shannon Fabre15*, Daniel O. Persky, MD15, Amit Agarwal15* and Anna Maria Frustaci, MD16*

1Department of Clinical Haematology, Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
2Alfred Hospital and Monash University, Melbourne, VIC, Australia
3Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
4Medical School, University of Western Australia, Perth, Western Australia, Australia
5Linear Clinical Research, Nedlands, Western Australia, Australia
6Division of Hematology-Oncology, Mayo Clinic-Florida, Jacksonville, FL
7Division of Hematology and Oncology, Weill Cornell Medicine, Long Island City, NY
8Concord Repatriation General Hospital, University of Sydney, Concord, NSW, Australia
9Stanford Cancer Institute, Stanford, CA
10David Geffen School of Medicine at UCLA, Los Angeles, CA
11Institute of Hematology "Seràgnoli", University of Bologna, Bologne, Italy
12St Vincent’s Hospital, Melbourne, Australia
13Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
14BeiGene (Shanghai) Co, Ltd, Shanghai, China
15BeiGene USA, Inc, San Mateo, CA
16ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy

3:15 PM

Sikander Ailawadhi1, Maria Gavriatopoulou2*, Jennifer Peterson, MD3*, Ioannis Ntanasis-Stathopoulos, MD, PhD, MSc4*, Ghassan El-Haddad5*, Ariel Grajales-Cruz6*, Aimaz Afrough7*, Moshe Y. Levy8*, Judith Trotman, FRACP9, Kimberly R. Doucette10*, Jorge J. Castillo, MD11, Francisco Hernandez-Ilizaliturri, MD12, Ajay K. Nooka13*, Shirley D'Sa, FRCP FRCPath MD(Res)14*, Ralph V. Boccia15*, Harsh Parmar, MD16, Carlos Fernández de Larrea, MD17, Guldane Cengiz Seval18*, Luiza Beatriz Goncalves Beber19*, Radhakrishnan Ramchandren, MD20*, Sheeba K. Thomas, MD21, Jarrod Longcor22*, Andrei Shustov22* and Larry D Anderson Jr., MD, PhD23

1Division of Hematology-Oncology, Mayo Clinic-Florida, Jacksonville, FL
2Alexandra General Hospital, Athens, Greece
3Mayo Clinic, Jacksonville
4Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
5Moffitt Cancer Center, Tampa, FL
6Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa
7UT Southwestern Simmons Cancer Center, Dallas, TX
8Texas Oncology, Dallas, TX
9University of Sydney, Concord Repatriation General Hospital, Concord, Australia
10MedStar Georgetown University Hospital, Washington, DC
11Dana-Farber Cancer Institute, Bing Center for Waldenström Macroglobulinemia, Boston, MA
12Department of Medicine (Lymphoma Section), Roswell Park Comprehensive Cancer Center, Buffalo, NY
13Emory Winship Cancer Institute, Atlanta, GA
14University College London Hospitals NHS Foundation Trust, London, United Kingdom
15Center for Cancer and Blood Disorders, Bethesda, MD
16Division of Multiple Myeloma, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ
17Hosp. Clinic I Provincial de Barcelona, Barcelona, Spain
18Ankara University Faculty of Medicine Cebeci Hospital, Ankara, Turkey
19Clinica de Oncologia Reichow, Blumenau, AL, BRA
20University of Tennessee Cancer Institute, Knoxville, TN
21Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
22Cellectar Biosciences, Florham Park, NJ
23Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX

3:30 PM

Tae Min Kim, MD, PhD1*, Seok-Goo Cho2*, Michal Taszner3*, Geoffrey Chong4, Jingxian Cai5*, Amulya Uppala5*, Aafia Chaudhry5, Hesham Mohamed5, Srikanth Ambati5 and John N. Allan, MD6

1Seoul National University Hospital, Seoul, Korea, Republic of (South)
2Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Korea, Republic of (South)
3Medical University of Gdańsk, Gdańsk, Poland
4Olivia Newton-John Cancer Wellness & Research Centre, Austin Hospital, Heidelberg, VIC, Australia
5Regeneron Pharmaceuticals, Inc., Tarrytown, NY
6Division of Hematology and Oncology, Weill Cornell Medicine, Long Island City, NY

3:45 PM

Robert J. Kreitman, MD1, Hao-Wei Wang, MD, PhD2*, Dana I. Delgado Colon, MD2*, Hong Zhou, BS1*, Evgeny Arons, PhD1*, Mark Raffeld, MD2*, Liqiang Xi, MD2*, Julie Feurtado, RN3*, Lacey James, CRNP1*, Raul C. Braylan, MD4, Katherine R. Calvo, MD, PhD4, Irina Maric, MD, MSc4 and Constance M. Yuan, MD, PhD2*

1Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD
2Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD
3Office of Research Nursing, National Cancer Institute, National Institutes of Health, Bethesda, MD
4Hematology Section, Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD

4:00 PM

Sattva S. Neelapu, MD1, Julio C. Chavez, MD2, Alison R. Sehgal, MD3, Narendranath Epperla, MD MS4, Matthew Ulrickson, MD5, Emmanuel Bachy, MD, PhD6, Pashna N. Munshi, MD7, Carla Casulo, MD8, David G. Maloney, MD, PhD9, Sven de Vos, MD, PhD10*, Ran Reshef, MD, MSc11, Lori A. Leslie, MD12*, Olalekan O. Oluwole, MD, MPH, MBBS13, Ibrahim Yakoub-Agha, MD, PhD14*, Rashmi Khanal, MD15, Joseph D. Rosenblatt, MD16*, Jacob Wulff, DrPH17*, Rhine Shen, PhD17*, Wangshu Zhang, PhD17*, Soumya Poddar17*, Harry Miao, MD, PhD17, Olga Nikolajeva, MD17* and Caron A. Jacobson, MD, MMSc18

1The University of Texas MD Anderson Cancer Center, Houston, TX
2Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
3UPMC Hillman Cancer Center, Pittsburgh, PA
4The Ohio State University Comprehensive Cancer Center, Columbus, OH
5Banner MD Anderson Cancer Center, Gilbert, AZ
6Centre Hospitalier Lyon Sud, Pierre-Bénite, France
7Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
8Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY
9Fred Hutchinson Cancer Center, Seattle, WA
10Ronald Reagan University of California Los Angeles Medical Center, Santa Monica, CA
11Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY
12John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, NJ
13Vanderbilt University Medical Center, Nashville, TN
14CHU de Lille, Université de Lille, INSERM U1286, Infinite, 59000, Lille, France
15Fox Chase Cancer Center, Philadelphia, PA
16University of Miami Sylvester Comprehensive Cancer Center, Miami, FL
17Kite, a Gilead Company, Santa Monica, CA
18Dana-Farber Cancer Institute, Boston, MA

*signifies non-member of ASH